{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"137"}]}],"title":"Any TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"29"}]}],"title":"Any serious TEAEs"},{"categories":[{"measurements":[{"groupId":"OG000","value":"100"}]}],"title":"Any TEAEs of special interest"}],"denoms":[{"counts":[{"groupId":"OG000","value":"240"}],"units":"Participants"}],"description":"The number of patients with each type of event is summarized. TEAEs were defined as adverse events (AEs) that started on or after the day of the first instillation of UGN-102 or pre-treatment AEs that worsened during the study.","groups":[{"description":"6 once-weekly intravesical instillations of UGN-102 (75 mg mitomycin).","id":"OG000","title":"UGN-102"}],"paramType":"COUNT_OF_PARTICIPANTS","populationDescription":"All patients who received any dose of UGN-102.","reportingStatus":"POSTED","timeFrame":"Up to 21 months","title":"Number of Participants With Treatment-emergent Adverse Events (TEAEs), Serious TEAEs, and TEAEs of Special Interest","type":"SECONDARY","unitOfMeasure":"Participants"}